Genmab — November 2019

[mobbyduck1]

det virker lidt underligt, er da ret så betydeligt, men åbenbart ikke nok til en fondsbørsmeddelse

[Sukkeralf]

Mener normalen er, at man ikke kommer med børsmeddelse på den slags studier !

[Bulder]

Havde det været et Janssen studie, havde de da gjort det. ASH LB har prestige.

[E_L]

innovaTV 208 adds an extra trial arm, 40 more patients, and is extended by 1 year https://clinicaltrials.gov/ct2/history/NCT03657043?A=15&B=16&C=merged#StudyPageTop

[Sukkeralf]

And how should we think about that - good or bad ?

[E_L]

the Dara atezolizumab NSCLC trial set to completed
https://clinicaltrials.gov/ct2/history/NCT03023423?A=28&B=29&C=merged#StudyPageTop

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[JKY_VH]

luk i 1516 et lille +

[Bella1]

Skruen er i vandet

[Solsen]

Bulder sparede rødvinen

[Solsen]

Jeg må studere Candor mere. Troede ikke den kombi var vigtig. Er der nogen der har input ud over det vigtige i at dara indgår i alle betydende kombinationer.

[E_L]

https://twitter.com/Rfonsi1/status/1197526159237505024

[E_L]

Usmani also recently started a Dara-KRd so he must see something

[Solsen]

The mentioned kombi must be unaffordable.

[E_L]

by the time that trial is done, 1 of those 4 will be off-patent. (Trying to look at the bright side )

[Bulder]

De skriver sådan set i introduktionen til Candor abs, hvorfor det er vigtigt: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these agents or discontinue them due to toxicity. There is a need for novel, efficacious, and tolerable regimens that can treat MM pts who are exposed or refractory to LEN or BTZ.

[bibob]

Candor må trods alt være vigtigt når den ( helt uventet ) får BT.

[transalp]

Go morgen.. stadig med meget godt i ve te

[transalp]

Vente..

[Helge_LarsenPI-redaktør]

God morgen.